Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma.
Diego Luigi CortinovisPaolo BidoliStefania CanovaFrancesca ColoneseMaria GemelliMaria Luisa LavitranoGiuseppe Luigi BannaStephen V LiuAlessandro MorabitoPublished in: Cancers (2021)
Small cell lung cancer (SCLC) is one of the deadliest thoracic neoplasms, in part due to its fast doubling time and early metastatic spread. Historically, cytotoxic chemotherapy consisting of platinum-etoposide or anthracycline-based regimens has demonstrated a high response rate, but early chemoresistance leads to a poor prognosis in advanced SCLC. Only a fraction of patients with limited-disease can be cured by chemo-radiotherapy. Given the disappointing survival rates in advanced SCLC, new cytotoxic agents are eagerly awaited. Unfortunately, few novel chemotherapy drugs have been developed in the latest decades. This review describes the results and potential application in the clinical practice of novel chemotherapy agents for SCLC.
Keyphrases
- locally advanced
- poor prognosis
- small cell lung cancer
- squamous cell carcinoma
- rectal cancer
- long non coding rna
- clinical practice
- radiation therapy
- early stage
- single cell
- spinal cord
- photodynamic therapy
- cell therapy
- mesenchymal stem cells
- chemotherapy induced
- bone marrow
- stem cells
- risk assessment
- spinal cord injury
- brain metastases
- anti inflammatory